Phase I/II trial of high affinity natural killer cells (haNK) in combination with ALT-803 for the treatment of bladder cancer
Latest Information Update: 15 Feb 2022
At a glance
- Drugs CST 101 (Primary) ; Nogapendekin alfa inbakicept (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 26 May 2016 New trial record
- 17 May 2016 This trial is expected to initiate in the second half of 2016, according to a NantKwest media release.